Amylyx Pharmaceuticals (AMLX) Other Non-Current Assets (2021 - 2025)
Historic Other Non-Current Assets for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $2.5 million.
- Amylyx Pharmaceuticals' Other Non-Current Assets rose 41867.22% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year increase of 41867.22%. This contributed to the annual value of $24000.0 for FY2024, which is 9657.63% down from last year.
- Latest data reveals that Amylyx Pharmaceuticals reported Other Non-Current Assets of $2.5 million as of Q3 2025, which was up 41867.22% from $11000.0 recorded in Q1 2025.
- In the past 5 years, Amylyx Pharmaceuticals' Other Non-Current Assets ranged from a high of $2.5 million in Q3 2025 and a low of $11000.0 during Q1 2025
- Its 5-year average for Other Non-Current Assets is $559666.7, with a median of $466000.0 in 2022.
- Data for Amylyx Pharmaceuticals' Other Non-Current Assets shows a peak YoY increase of 41867.22% (in 2025) and a maximum YoY decrease of 9776.88% (in 2025) over the last 5 years.
- Amylyx Pharmaceuticals' Other Non-Current Assets (Quarter) stood at $200000.0 in 2021, then skyrocketed by 133.0% to $466000.0 in 2022, then skyrocketed by 50.43% to $701000.0 in 2023, then crashed by 96.58% to $24000.0 in 2024, then skyrocketed by 10316.67% to $2.5 million in 2025.
- Its Other Non-Current Assets stands at $2.5 million for Q3 2025, versus $11000.0 for Q1 2025 and $24000.0 for Q4 2024.